A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency by H\uf6ybye, Charlotte et al.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.DOI: 10.1530/EC-17-0007
http://www.endocrineconnections.org © 2017 The authors



































A phase 2 trial of long-acting 
TransCon growth hormone in adult 
GH deficiency
Charlotte Höybye1, Andreas F H Pfeiffer2, Diego Ferone3, 
Jens Sandahl Christiansen4, David Gilfoyle5, Eva Dam Christoffersen5, 
Eva Mortensen6, Jonathan A Leff6 and Michael Beckert5
1Department of Endocrinology, Metabolism and Diabetology, Karolinska University Hospital and 
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
2Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Endokrinologie & 
Stoffwechselmedizin, Berlin, Germany
3IRCCS AOU San Martino-IST, Università di Genova – Endocrinologia DiMI, Dipartimento di Medicina 
Interna e Specialità Mediche, & CEBR, Centro di Eccellenza per la Ricerca Biomedica, Genova, Italy
4Medicinsk Endokrinologist Afd., MEA, NBG, Århus Sygehus, Århus, Denmark
5Ascendis Pharma A/S, Hellerup, Denmark
6Ascendis Pharma Inc., Palo Alto, California, USA
Abstract
TransCon growth hormone is a sustained-release human growth hormone prodrug 
under development in which unmodified growth hormone is transiently linked to 
a carrier molecule. It is intended as an alternative to daily growth hormone in the 
treatment of growth hormone deficiency. This was a multi-center, randomized, open-
label, active-controlled trial designed to compare the safety (including tolerability and 
immunogenicity), pharmacokinetics and pharmacodynamics of three doses of weekly 
TransCon GH to daily growth hormone (Omnitrope). Thirty-seven adult males and 
females diagnosed with adult growth hormone deficiency and stable on growth hormone 
replacement therapy for at least 3 months were, following a wash-out period, randomized 
(regardless of their pre-study dose) to one of three TransCon GH doses (0.02, 0.04 and 
0.08 mg GH/kg/week) or Omnitrope 0.04 mg GH/kg/week (divided into 7 equal daily doses) 
for 4 weeks. Main outcomes evaluated were adverse events, immunogenicity and growth 
hormone and insulin-like growth factor 1 levels. TransCon GH was well tolerated; fatigue 
and headache were the most frequent drug-related adverse events and reported in all 
groups. No lipoatrophy or nodule formation was reported. No anti-growth hormone-
binding antibodies were detected. TransCon GH demonstrated a linear, dose-dependent 
increase in growth hormone exposure without accumulation. Growth hormone maximum 
serum concentration and insulin-like growth factor 1 exposure were similar after TransCon 
GH or Omnitrope administered at comparable doses. The results suggest that long-acting 
TransCon GH has a profile similar to daily growth hormone but with a more convenient 
dosing regimen. These findings support further TransCon GH development.
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Hypothalamic–pituitary diseases and/or injury can lead to 
adult growth hormone deficiency (AGHD) (1). The decrease 
(or total loss) of growth hormone (GH) production, with a 
subsequent disruption in the hormone’s relationship with 
insulin-like growth factor 1 (IGF1), leads to abnormal body 
composition and metabolism as well as psychological 
impairment (1, 2). Left untreated, AGHD is associated 
with decreased bone mineral density, increased risk of 
cardiovascular mortality as compared to age-matched 
controls and poor quality of life (3, 4, 5, 6).
Recombinant human GH, also known as somatropin, 
is produced by inserting cDNA coding for human GH into 
Escherichia coli. It became commercially available in the 
mid-1980s and is identical to endogenous GH. To date, 
AGHD standard-of-care treatment consists of daily 
subcutaneous GH injections. However, a significant 
portion of patients are poorly adherent to treatment (7), up 
to 65% in one study, attributed to the inconvenience and 
discomfort of daily injections, concerns about efficacy and 
treatment length beyond 2 years (8). Caremark Inc. data 
showed that prescription refills dropped to 54% within the 
first 11 months of GH therapy initiation (8). Invariably, 
poor adherence leads to suboptimal efficacy (6). Given 
that GH replacement has benefits throughout life (1), 
many patients will likely need treatment for years. Thus, 
a safe and efficacious product with less frequent dosing 
would be a considerable improvement over currently 
available daily regimens and may lead to increased 
adherence, with consequent positive physiological effects 
and better quality of life.
Given that GH receptors are located on virtually 
every cell in the body and facilitate GH’s many functions, 
any GH replacement product should be able to reach GH 
receptors. Currently, a variety of long-acting GH therapies 
are in development. Most are chemically modified 
proteins that often extend GH’s half-life by molecular 
enlargement. However, this approach is potentially 
problematic if tissue penetration is inadequate. For 
example, GH crosses the blood–brain barrier to exert 
its cognitive effects (9) as well as directly stimulates 
osteoblasts in bone formation (10). If a small molecule 
becomes too bulky and cannot reach its receptors, 
efficacy may be compromised (11). Thus, for any long-
acting GH to have the multi-faceted effects necessary 
for successful AGHD treatment, it is important that it 
mimic endogenous GH as closely as possible in size and 
other properties.
TransCon GH is a sustained-release inactive prodrug 
consisting of a parent drug, unmodified 22 kDa GH 
equivalent to endogenous GH, transiently bound to a 
carrier molecule, methoxy polyethylene glycol (mPEG), 
via a proprietary low-molecular-weight TransCon Linker. 
The inert mPEG acts as a carrier, extending GH circulation 
time in the body through a shielding effect that minimizes 
GH receptor binding and renal excretion, thereby largely 
inactivating GH until its release (Fig. 1). Over a one-week 
period, TransCon GH frees fully active GH via auto-
hydrolysis of the TransCon linker in a controlled manner 
based on physiologic pH and temperature. As such, the 
TransCon technology is designed to maintain the same 
mode of action and distribution as daily administered 
GH by allowing the sustained release of unmodified 
recombinant GH.
The purpose of this investigation was to compare 
the safety (including tolerability and immunogenicity), 
pharmacokinetics (PK) and pharmacodynamics (PD) of 
three different doses of weekly TransCon GH to that of 
daily recombinant GH in patients with AGHD.
Figure 1
TransCon GH, a sustained-release inactive prodrug consisting of parent drug, unmodified GH, transiently bound to a carrier, methoxypolyethylene 
glycol (mPEG), via a proprietary linker that is auto-hydrolyzed under physiologic pH and temperature.
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This was a Phase 2 multi-center, randomized, open-
label, parallel group, active-controlled trial of three 
different doses of weekly TransCon GH compared to daily 
Omnitrope. The trial was conducted at 4 reference centers 
in Sweden, Denmark, Germany and Italy. Institutional 
review board and independent ethics committee approval 
as well as signed informed consent from subjects was 
obtained prior to any trial-specific procedures. The 
ClinicTrials.gov identifier is NCT01247675. The EudraCT 
number is 2010-021523-28.
Population
Males and females (between the ages of 20 and 70 years 
with a body mass index (BMI) of 19.0–36.0 kg/m2) 
diagnosed with AGHD (defined according to the Growth 
Hormone Research Society Consensus Guidelines of 1998 
and 2007) (1, 12) who were stable on GH replacement 
therapy for at least 3 months were enrolled. Fertile females 
were required to have a negative pregnancy test at the time 
of enrollment and agree to use contraception during the 
trial. Subjects were excluded if they had a known history 
of anti-GH antibodies; were breast-feeding; had a current 
or (within 5  years) prior malignancy; had uncontrolled 
diabetes mellitus (defined as an HbA1c over 8.0% and/or 
receiving insulin treatment) or had other significant 
comorbidities that would preclude participation in a 
clinical trial.
Trial protocol
Subjects attended a screening visit during which their 
medical history was reviewed and a physical examination 
(including vital signs, height, and weight) and an 
electrocardiogram (ECG) were performed. Screening 
laboratory tests included GH, IGF1, a pregnancy test 
(for fertile females), hematology, chemistry, coagulation, 
urinalysis, insulin, HbA1c and lipids.
Subjects then entered a 14- to 21-day wash-out 
period after cessation of daily GH after which they were 
randomized (regardless of their pre-study dose) to one 
of 3 TransCon GH (ACP-001) doses, i.e., 0.02, 0.04 or 
0.08 mg GH/kg/week or Omnitrope 0.04 mg GH/kg/week 
(divided into 7 equal daily doses) for 4 weeks. On Days 1, 
8, 15 and 22, TransCon GH-treated subjects were dosed 
on-site subcutaneously via a syringe with a 30-gauge 
needle at rotating locations on the abdomen. From Days 
1 to 28, Omnitrope-treated subjects self-dosed at home 
subcutaneously with the 31-gauge Omnitrope Pen at 
rotating locations on the abdomen and thigh.
Safety, pharmacokinetics, and 
pharmacodynamics assessments
Safety assessments, made prior to dosing at select visits 
as well as at the safety follow-up visit (Day 42), included 
vital signs with weight, physical examination, ECG, 
immunogenicity evaluation and clinical laboratory 
testing. Serum for anti-GH-binding antibodies was drawn 
at screening and Days 0, 8, 22, 29 and 42 and analyzed 
using a validated ELISA (Millipore BioPharma Services, 
currently known as Eurofins Pharma Bioanalysis Services 
UK Limited). If samples were confirmed anti-GH binding 
antibody positive, samples were subsequently analyzed for 
the presence of neutralizing antibodies using a validated 
cell-based proliferation assay. Clinical laboratory safety 
tests, including hematology, chemistry, coagulation, 
urinalysis, insulin, HbA1c and lipids were drawn on Days 
0, 2, 8, 15, 22, 29 and 42. Results in standard international 
units were converted using the Society for Biomedical 
Diabetes Research SI Unit Conversion Calculator (http://
www.soc-bdr.org/rds/authors/unit_tables_conversions_
and_genetic_dictionaries/conversion_in_si_units/index_
en.html). Subjects were monitored for adverse events (AEs) 
throughout the study. Local tolerability was evaluated by 
injection site reactions (defined as erythema, swelling and 
pain) at 8, 12 and 24 h after dose on Days 8 and 15 as well 
as by patient diary.
Blood samples for PK and PD assessments in the 
TransCon GH cohorts were collected at Day 0 and pre-
dose on Days 1, 8, 15 and 22. After the first (Day 1) and 
fourth (Day 22) doses, post-dose samples were collected 
repeatedly for up to seven (Day 8) and twenty (Day 42) 
days, respectively. Additional samples were collected on 
Days 9 and 21. In Omnitrope-treated subjects, samples 
were collected at pre-dose on Day 1 and then repeatedly 
for up to 24 h after dose administration on Days 1 and 22. 
Additional samples were collected pre-dose on 14 occasions 
(Days 3–28) and post-dose on Days 29, 31, 35 and 42.
Analyses of GH and IGF1 were performed by 
Celerion Inc. (Lincoln, NE, USA). GH was quantified in 
serum by a validated commercially available sandwich 
ELISA (ALPCO Diagnostics, Salem, NH, USA), whereas 
plasma IGF1, the primary PD biomarker, was quantified 
by a validated commercially available sandwich ELISA 
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(R&D Systems) using WHO International Standard 02/254 
as reference material.
Baseline GH was defined as the last available 
measurement prior to the first dose (usually Day 1) 
and set to zero as all baseline samples were below the 
quantification limit. Maximum GH concentration (Cmax) 
was defined as the highest serum concentration achieved 
post-dose following Days 1 and 22 administrations for 
all cohorts. Area under the curve (AUC) for TransCon 
GH-treated subjects was calculated based on drug 
concentration at time 0–168 h after-dose on Days 1 and 
22 using the linear trapezoidal rule for the ascending 
part of the concentration–time curve and the logarithmic 
trapezoidal rule for the descending part. AUC for 
Omnitrope-treated subjects was calculated based on drug 
concentration at time 0–24 h post-dose on Days 1 and 22 
multiplied by 7 to be comparable to weekly TransCon GH. 
For subjects with fewer than three consecutive data points 
above the lower limit of quantification (LLOQ), AUC was 
not calculated, and these subjects were excluded from the 
overall mean AUC calculation.
For PD, baseline IGF1 was defined as the last available 
measurement prior to the first dose (usually Day 1). Time 
to maximum efficacy (TEmax) was defined as the time 
needed to attain the maximum IGF1 effect (Emax). The 
IGF1 area under the effect curve (AUEC) was calculated 
based on the difference of AUEC areas above and below 
zero (ie, AUEC = AUECabove − AUECbelow) for both TransCon 
GH and Omnitrope-treated subjects using the same 
methodology as for PK.
Statistical analysis
Demographics, vital signs including height and weight 
and ECG as well as GH, IGF1 and anti-GH antibody data 
were analyzed by descriptive statistics using SAS, version 
9 or higher. AEs were summarized but not statistically 
evaluated. Demographics, baseline characteristics, safety 
and tolerability were analyzed in all subjects who were 
randomized and received at least one dose of test product 
with an analysis of variance performed for age, weight and 
height. PK and PD parameters were assessed for subjects 
who received at least one dose of test product, had at least 
one primary variable measurement drawn and attended 
all visits up to and including Day 28; PK and PD analysis 
were performed using WinNonLin, version 5.2.
Results
Thirty-seven subjects satisfied inclusion and exclusion 
criteria and were randomized into four cohorts. Cohort 1 
(n = 10) received TransCon GH 0.02 mg/kg/week, Cohort 2 
(n = 10) received TransCon GH 0.04 mg/kg/week, Cohort 3 
(n = 9) received TransCon GH 0.08 mg/kg/week and Cohort 
4 (n = 8) received Omnitrope 0.04 mg/kg/week (in 7 divided 
doses). All 37 subjects were included in demographic and 
baseline characteristic analyses (Table 1). The majority of 
patients (28/37; 76%) had multiple pituitary hormone 
deficiencies, i.e., one or more hypothalamic–pituitary 
axes deficiencies in addition to AGHD.
Four subjects withdrew from the study, two each from 
Cohorts 1 and 2. In Cohort 1, one subject withdrew due 
to comorbidities; the other withdrew for personal reasons; 
both were, however, included in the PK and PD analyses. 
In Cohort 2, each subject withdrew due to adverse events 
with their withdrawal occurring before Day 28; both were 
therefore excluded from the PK and PD analyses, leaving 
35 subjects. Further details about withdrawal due to 
adverse events may be found under ‘Safety’ section.
The cohorts were balanced with respect to gender; 18 
(49%) were male, 19 (51%) were female. All were Caucasian 
except two who were Arabic and non-Caucasian Hispanic, 
respectively. Mean age was 49.5  years, mean BMI was 
28 kg/m2 and mean IGF1 at baseline after wash-out was 
45.0 ng/mL.
Table 1 Demographic and baseline characteristics of TransCon GH and Omnitrope cohorts.
 
 
Cohort 1 TransCon GH 
0.02 mg/kg/week
Cohort 2 TransCon GH 
0.04 mg/kg/week
Cohort 3 TransCon GH 
0.08 mg/kg/week
Cohort 4 Omnitrope 
0.04 mg/kg/week
At screening n = 10 n = 10 n = 9 n = 8
Male, female 5, 5 4, 6 4, 5 5, 3
Mean age (years) (s.d.) 55.7 (12.6) 45.9 (15.0) 51.6 (18.1) 44.0 (15.7)
Mean weight (kg) (s.d.) 82.3 (19.8) 79.6 (17.0) 92.5 (20.5) 74.7 (16.6)
Mean height (cm) (s.d.) 171.7 (10.9) 168.5 (11.4) 172.7 (10.0) 170.1 (12.9)
Mean BMI (kg/m2) (s.d.) 27.6 (4.4) 27.9 (4.4) 30.7 (4.4) 25.7 (4.4)
At Day 0 n = 10 n = 8 n = 9 n = 8
Mean IGF-1 (ng/mL) (s.d.) 41.9 (16.8) 42.8 (26.9) 42.6 (12.7) 54.0 (25.6)
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A total of 178 AEs were reported; 78.4% (29/37) of subjects 
experienced at least 1 AE and 51.4% (19/37) experienced 
at least 1 AE definitely, probably or possibly related to the 
study medication. Fatigue and headache were reported in 
all groups and were the most frequent drug-related AEs 
observed (Table 2).
Treatment-related AE incidence was similar in 
TransCon GH Cohorts 1 and 3 and Omnitrope Cohort 4 
(40, 44, and 50%, respectively) compared to 70% in the 
TransCon GH Cohort 2 (Table 3). No AEs led to death. Two 
serious adverse events (SAEs) occurred in one subject, a 
70-year-old female with a history of multiple adrenal crises 
in Cohort 1 receiving TransCon GH 0.02 mg/kg/week. Six 
days after treatment initiation, she again experienced 
a severe adrenal crisis requiring hospitalization. After 
recovery, she experienced a second SAE, moderate 
pleuritic chest pain likely caused by a pulmonary infiltrate. 
Although neither SAE was considered related to TransCon 
GH, the patient was withdrawn from the trial 7 days after 
the fourth injection.
Two additional subjects withdrew because of AEs. One 
subject in Cohort 2 receiving TransCon GH 0.04 mg/kg/
week developed mild diarrhea one day after treatment 
initiation, considered possibly related to the study drug. 
A second subject receiving the same TransCon GH dose 
experienced a mild influenza-like illness two days after 
treatment initiation, considered unlikely to be related to 
the study drug.
No lipoatrophy or nodule formation at the injection 
site was reported. Nine subjects experienced at least one 
injection site reaction; there was no clear difference in 
these reactions between TransCon GH and Omnitrope-
treated subjects. Eight subjects (2 in Cohort 1 and 3, 
respectively; 3 in Cohort 2 and 1 in Cohort 4) experienced 
injection site erythema. One subject in both Cohorts 1 
and 2 experienced injection site pain, whereas 1 subject in 
Cohort 1 experienced injection site swelling.
One subject treated with GH since 2007 was found 
to possess pre-existing non-neutralizing anti-GH-binding 
antibodies. Of the remaining 36 subjects, anti-GH-binding 
antibodies were not detected.
Table 2 Treatment-emergent adverse events occurring in >1 subject in any cohort.
 
 
Cohort 1 TransCon GH 
0.02 mg/kg/week n = 10 (%)
Cohort 2 TransCon GH 
0.04 mg/kg/week n = 10 (%)
Cohort 3 TransCon GH 
0.08 mg/kg/week n = 9 (%)
Cohort 4 Omnitrope 
0.04 mg/kg/week n = 8 (%)
Fatigue 3 (30) 3 (30) 1 (11) 2 (25)
Headache 2 (20) 3 (30) 2 (22) 2 (25)
Oropharyngeal pain 1 (10) 3 (30) 2 (22) 2 (25)
Nausea 0 (0) 3 (30) 2 (22) 1 (13)
Nasopharyngitis 0 (0) 1 (10) 2 (22) 2 (25)
Diarrhea 1 (10) 2 (20) 0 (0) 1 (13)
Arthralgia 2 (20) 1 (10) 1 (11) 0 (0)
Application site erythema 2 (20) 0 (0) 0 (0) 1 (13)
Application site  
induration
2 (20) 0 (0) 0 (0) 1 (13)
Cough 0 (0) 3 (30) 0 (0) 0 (0)
Back pain 1 (10) 0 (0) 2 (22) 0 (0)
Asthenia 2 (20) 0 (0) 0 (0) 0 (0)
Influenza-like illness 0 (0) 2 (20) 0 (0) 0 (0)
Affect lability 2 (20) 0 (0) 0 (0) 0 (0)
Depressed mood 2 (20) 0 (0) 0 (0) 0 (0)
Insomnia 2 (20) 0 (0) 0 (0) 0 (0)
Stress 0 (0) 0 (0) 0 (0) 2 (25)
Hematuria 0 (0) 0 (0) 0 (0) 2 (25)
Table 3 Summary of adverse events by cohort.
 
 
Cohort 1 TransCon GH 
0.02 mg/kg/week n = 10 (%)
Cohort 2 TransCon GH 
0.04 mg/kg/week n = 10 (%)
Cohort 3 TransCon GH 
0.08 mg/kg/week n = 9 (%)
Cohort 4 Omnitrope 
0.04 mg/kg/week n = 8 (%)
Reported 6 (60) 9 (90) 7 (78) 7 (88)
Serious 1 (10) 0 (0) 0 (0) 0 (0)
Treatment related 4 (40) 7 (70) 4 (44) 4 (50)
Leading to 
withdrawal
1 (10) 2 (20) 0 (0) 0 (0) 
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The mean BMI of TransCon GH Cohorts 1–3 was 
28.8 kg/m2 at screening and 29.0 kg/m2 at Day 29 compared 
to 25.7 kg/m2 and 25.8 kg/m2 for Omnitrope Cohort 4, 
respectively (Table  4). Of the 19 subjects experiencing 
treatment-related AEs, 7 of 15 TransCon GH vs 1 of 4 
Omnitrope-treated subjects had a BMI ≥30.0. The mean 
total cholesterol of TransCon GH Cohorts 1–3 decreased 
from 213 on Day 0 to 203 mg/dL on Day 29 compared to 
a decrease from 208 to 187 mg/dL in Omnitrope Cohort 
4, respectively. For both TransCon GH Cohorts 1–3 and 
Omnitrope Cohort 4, HbA1c was 5.7% at Day 0 and 5.6% 
at Day 29.
Pharmacokinetics
The GH serum concentration profiles after subcutaneous 
administration of TransCon GH from Days 1 to 42 are 
presented in Fig.  2. TransCon GH released GH in a 
sustained manner over the intended 168-h dose interval. 
A linear, dose-dependent increase in GH exposure (Cmax 
and AUC0–168 h) was observed, without accumulation, 
after multiple administrations of TransCon GH. As 
expected, GH median Tmax was reached more slowly 
than that of Omnitrope administration, ranging from 
14–16 h compared to 2–4 h for Omnitrope. GH peak 
exposures (Cmax) after administration of TransCon GH 
or Omnitrope at comparable doses (0.04 mg/kg/week) 
were similar at both Weeks 1 and 4. The PK summary for 
Weeks 1 and 4 is presented in Table 5. As the observed 
GH PK profile reflects TransCon GH linker hydrolysis 
kinetics, TransCon GH and GH PK show similar overall 
profiles, dose dependency and lack of accumulation (data 
not shown).
Of note, one subject in TransCon GH Cohort 3 had 
very high GH levels at 4 and 6 h after the first injection, 
confirmed by sample reanalysis. The remainder of this 
subject’s GH profile was comparable to others in the 
cohort. As such, the spike was attributed to sample 
mishandling, and the two data points were excluded from 
the PK analysis.
Pharmacodynamics
Plasma IGF1 levels increased above baseline at all doses of 
TransCon GH and Omnitrope (Fig. 3). After repeat dosing 
of TransCon GH and Omnitrope, IGF1 trough levels 
remained above baseline. Maximum observed response 
(Emax) was higher after the fourth dose compared to the 
first dose, consistent with multiple GH doses required 
to establish a stable IGF1 response. Baseline corrected 
IGF1 exposure (Emax and AUEC0–168 h) after the first and 
fourth doses was essentially linear across TransCon 
GH doses. IGF1 exposure after administration of 
TransCon GH (AUEC0–168 h) or Omnitrope (AUEC0–24 h × 7) 





Cohort 1 TransCon 
GH 0.02 mg/kg/week
Cohort 2 TransCon 
GH 0.04 mg/kg/week
Cohort 3 TransCon 
GH 0.08 mg/kg/week
Cohort 4 Omnitrope 
0.04 mg/kg/week
Mean BMI (kg/m2) (s.d.)  (n = 9) (n = 8) (n = 9) (n = 8)
 Screening 27.5 (4.7) 28.2 (3.8) 30.7 (4.4) 25.7 (4.4)
 Day 29 27.6 (4.6) 28.4 (4.0) 30.9 (4.4) 25.8 (4.7)
Mean total cholesterol (mg/dL) (s.d.)  (n = 8) (n = 8) (n = 9) (n = 8)
 Day 0 228 (63) 203 (48) 209 (33) 208 (47)
 Day 29 221 (50) 194 (41) 194 (25) 187 (31)
Mean HDL cholesterol (mg/dL) (s.d.)  (n = 8) (n = 8) (n = 9) (n = 8)
 Day 0 67 (27) 54 (17) 57 (13) 64 (26)
 Day 29 63 (26) 51 (18) 55 (14) 58 (23)
Mean LDL cholesterol (mg/dL) (s.d.)  (n = 8) (n = 8) (n = 9) (n = 8)
 Day 0 138 (53) 126 (26) 127 (34) 122 (40)
 Day 29 132 (41) 120 (30) 113 (26) 109 (27)
Mean triglycerides (mg/dL) (s.d.)  (n = 8) (n = 8) (n = 9) (n = 8)
 Day 0 124 (55) 122 (74) 145 (103) 97 (68)
 Day 29 140 (71) 123 (76) 129 (47) 100 (103)
Mean glucose (mg/dL) (s.d.)  (n = 8) (n = 7) (n = 9) (n = 7)
 Day 0 77 (13) 89 (23) 74 (19) 93 (30)
 Day 29 80 (12) 84 (20) 78 (19) 85 (14)
Mean HbA1c (%) (s.d.)  (n = 3) (n = 3) (n = 4) (n = 2)
 Day 0 5.9 (0.2) 5.6 (0.5) 5.7 (0.5) 5.7 (NA)
 Day 29 5.8 (0.2) 5.5 (0.3) 5.6 (0.4) 5.6 (NA)
NA, not applicable.
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0.04 mg/kg/week was similar. The PD summary at steady 
state is presented in Table 6.
Discussion
Overall, TransCon GH was well tolerated; the two SAEs 
in one patient were not considered treatment related. 
In contrast to several other weekly GH products based 
on protein enlargement (13, 14, 15), no lipoatrophy 
or nodule formation occurred at injection sites in this 
trial. And no treatment-emergent anti-GH antibodies 
were detected. Clinical safety parameters were stable 
with similar directional trends between TransCon 
GH and Omnitrope. After repeat doses, TransCon GH 
demonstrated a linear, dose-dependent increase in GH 
Figure 2
GH serum concentration (pg/mL), arithmetic means (+s.d.), linear scale, untransformed data, following weekly administration of TransCon GH or daily 
Omnitrope from screening to day 42. Omnitrope-treated subjects sampled intensively for 24 h after doses on Days 1 (0 h) and 22 (504 h). All other time 
points between Day 3 (48 h) to Day 21 (480 h) and Day 24 (552 h) to Day 42 (948 h) were sampled prior to dosing. Data from two time points from one 
Cohort 3 subject were excluded due to sample mishandling with subsequent outlier results.
Table 5 Summary of growth hormone PK for all 4 cohorts (Weeks 1 and 4; untransformed data).a
 
 
Cohort 1 TransCon GH 
0.02 mg/kg/week
Cohort 2 TransCon GH 
0.04 mg/kg/week
Cohort 3 TransCon GH 
0.08 mg/kg/week
Cohort 4 Omnitrope 
0.04 mg/kg/week
Week 1 4 1 4 1 4 1 4
Median Tmax (h) (n = 8) (n = 9) (n = 8) (n = 8) (n = 9) (n = 9) (n = 8) (n = 7)
 14.0 1.0 16.0 14.1 16.0 16.0 2.1 4.0
Mean Cmax (ng/mL) (s.d.) (n = 10) (n = 10) (n = 8) (n = 8) (n = 9) (n = 9) (n = 8) (n = 8)
 0.8 (0.8) 1.2 (0.8) 1.9 (1.1) 1.9 (0.9) 4.0 (0.8) 3.8 (2.0) 2.1 (0.9) 2.0 (1.1)
Mean AUC (h * ng/mL) (s.d.) (n = 4) (n = 4) (n = 8) (n = 7) (n = 9) (n = 9) (n = 7) (n = 2)
 86 (31) 89 (22) 133 (39) 154 (32) 302 (94) 318 (197) 132 (25) 146 (NA)
Mean accumulation, AUCb  (n = 3)  (n = 7)  (n = 9)  (n = 2)
 NA 1.4 NA 1.2 NA 1.0 NA 1.1
Cmax and AUC values are reported as arithmetic means (s.d.).
aExcludes data from 2 mishandled samples from one subject. bMean accumulation ratio between AUC at Week 4 compared to Week 1 based on TransCon 
GH 0–168 h; Omnitrope (0–24 h) * 7.
NA, not applicable.
Downloaded from Bioscientifica.com at 07/15/2019 03:17:01PM
via Universita Studi di Genova
This work is licensed under a Creative Commons 
Attribution 4.0 International License.DOI: 10.1530/EC-17-0007
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd


















peak exposure without accumulation and a similar Cmax 
as compared to Omnitrope at equivalent weekly dosing. 
IGF1 exposure after equivalent dosing of TransCon GH 
and Omnitrope was also similar.
AGHD is associated with increased mortality, mainly 
due to cardiovascular risk. GH deficiency contributes 
to visceral obesity, leading to insulin resistance and 
dyslipidemia (especially high LDL), diabetes mellitus and 
chronic inflammation (specifically increased C-reactive 
protein). The net result is increased atherosclerosis and 
reduced cardiac function with a subsequent increased 
risk of cardiovascular events and mortality (16). In a 
study by Hoffman and coworkers, 166 AGHD subjects 
were treated with daily GH. After 12 months, they had 
significantly decreased total body fat, increased lean 
body mass and improvements in their total cholesterol 
and LDL (17). In their review of AGHD-randomized trial 
participants, Maison and coworkers also found that GH 
treatment is associated with a significant positive effect 
on cardiac function, attributed to the trophic effects of 
GH (18).
The current study was a Phase 2 PK, PD and dose-finding 
study, making definitive conclusions about the clinical 
safety parameters from a long-term perspective premature. 
However, TransCon GH mimicked the directional trend of 
similarly dosed Omnitrope across BMI, lipids and HbA1c. 
Given TransCon GH’s comparable results to Omnitrope 
with regard to GH serum concentration and the fact that 
the active drug in both cases is unmodified human GH, 
similar improvement in overall cardiovascular morbidity 
and mortality as compared to daily GH treatment 
might be expected in patients with AGHD who receive 
TransCon GH long term. This will need to be confirmed 
in future studies.
Figure 3
Plasma IGF1 response (ng/mL) to weekly TransCon GH or daily Omnitrope from Day 1 to 42, untransformed arithmetic mean (+s.d.).
Table 6 Summary of IGF1 PD for all 4 cohorts (Week 4; untransformed data).
 
 
Cohort 1 TransCon GH 
0.02 mg/kg/week
Cohort 2 TransCon GH 
0.04 mg/kg/week
Cohort 3 TransCon GH 
0.08 mg/kg/week
Cohort 4 Omnitrope 
0.04 mg/kg/week
Median TEmax
a (h) (n = 10) (n = 8) (n = 9) (n = 8)
 24.0 60.0 48.0 12.0
Mean Emax
a (ng/mL) (s.d.) (n = 10) (n = 8) (n = 9) (n = 8)
 71.8 (26.9) 108.6 (91.7) 125.6 (70.1) 109.8 (37.1)
AUECb (h * ng/mL) (s.d.) (n = 8) (n = 8) (n = 9) (n = 8)
 10,441 (4560) 14,314 (11,432) 17,851 (10,099) 16,656 (5624)
Emax and AUEC are reported as arithmetic means (s.d.).
aTransCon GH 0–168 h; Omnitrope 0–24 h. bTransCon GH 0–168 h; Omnitrope (0–24 h) * 7.
Downloaded from Bioscientifica.com at 07/15/2019 03:17:01PM
via Universita Studi di Genova
This work is licensed under a Creative Commons 
Attribution 4.0 International License.DOI: 10.1530/EC-17-0007
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd


















Daily GH therapy is supported by many years of safety 
data (19); GH replacement in AGHD is well tolerated, 
and there is no evidence of increased risk of de novo or 
recurrent malignancy (6). IGF1 is the best and most used 
serum marker for GH dose titration (1). From a safety 
perspective, it is therefore encouraging that TransCon 
GH-mediated IGF1 levels were similar to those seen for 
Omnitrope after administration of equivalent doses over 
4 weeks.
One subject, with a history of multiple prior adrenal 
crises, did suffer an adrenal crisis in this study. The 
investigator did not attribute it to TransCon GH. However, 
daily GH therapy may render recipients with low adrenal 
reserve hypoadrenal (20). Further study is needed to 
determine if daily and long-acting GH therapies share 
similar adrenal risks.
Unlike pediatric GH deficiency where dosing is 
based by weight, AGHD dosing is more complex and 
individualized, taking into account age, gender and IGF1 
levels (6). Upward (or downward) titration is required to 
maximize benefits and minimize side effects all while 
targeting normal age and gender IGF1 levels (21). It is worth 
noting that subjects in this trial were randomly assigned 
to fixed test drug dose levels irrespective of their pre-study 
GH dose, which may have been higher (or lower). Some 
AEs could therefore be anticipated as subjects were not 
necessarily placed on their ideal dose. That fatigue and 
headache were subsequently the most common AEs is not 
surprising given that they are considered typical of both 
GHD and GH treatment (22).
The expected low titer, non-neutralizing antibody 
development rate in children receiving Genotropin is 
approximately 5–12%; adults develop antibodies much 
less frequently than children (23, 24). One subject was 
found to have pre-existing non-neutralizing antibodies, 
likely due to long-term daily GH treatment, the levels of 
which did not change after dose. However, the remaining 
subjects did not develop anti-GH-binding antibodies.
This study had certain limitations. An approved long-
acting GH product for AGHD with similar safety, efficacy, 
tolerability and immunogenicity as Omnitrope was not 
available. Thus, this study is a comparison of two products 
with different dosing regimens, short-acting versus long-
acting GH. These different administration frequencies 
also made blinding unfeasible. The sample size was small 
with only 29 subjects receiving TransCon GH. However, 
AGHD is estimated to affect only 1 per 100,000 annually 
(6). The main efficacy endpoint was limited to IGF1 levels 
and thus did not require a large study. Due to sensitivity 
limitations of the GH assay, several subjects did not have 
concentration data supporting AUC calculations and were 
excluded. Mean GH AUC was therefore biased on the high 
side, particularly in Weeks 1 and 4 of TransCon GH Cohort 
1 and Week 4 of Omnitrope Cohort 4. Still, comparable 
Week 1 AUCs were observed between equivalent doses 
of TransCon GH Cohort 2 and Omnitrope Cohort 4 
supporting similarity in GH exposure.
Overall, weekly TransCon GH, with a mg to mg 
conversion to commercially available daily GH products, 
was found to be similar to daily Omnitrope at a GH 
equivalent dose in terms of adverse events, tolerability, 
immunogenicity, serum GH and plasma IGF1 levels. 
The results support efficacy trials in AGHD that will 
help evaluate TransCon GH’s long-term effects on body 
composition, bone metabolism and quality of life.
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